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Objective. Erythropoietin (EPO) is a key regulator of erythropoiesis, playing a role in both
the proliferation and differentiation oferythroid cells. One of the signaltransduction molecules
activated upon EPO stimulation is signal transducer and activator of transcription (STAT) 3.
Besides tyrosine 705phosphorylation ofSTAT3, serine727 phosphorylationhas beendescribed
uponEPOstimulation.Inthepresentstudy,weinvestigatedwhichmolecularpathwaysmediate
the STAT3 serine 727 phosphorylation and the functional implications of this phosphorylation.
Methods. The EPO-dependent erythroid cell line ASE2 was used to investigate which signaling
routes were involved in the STAT3 serine 727 phosphorylation. Western blotting using
phosphospeciﬁc antibodies was used to assess the phosphorylation status of STAT3 molecules.
Transfection analysis was performed to investigate the transactivational potential of STAT3,
and quantitative RT-PCR was used to study the in vivo gene expression of STAT3-
responsive genes.
Results. Western blotting of extracts of cells exposed to various chemical inhibitors revealed
that the MEK inhibitors PD98059 and U0126 abrogated the EPO-mediated STAT3 serine 727
phosphorylation without an effect on tyrosine phosphorylation. Further analysis showed that
MSK1isactivateddownstreamofERK,andretroviraltransductionswithkinase-inactiveMSK1
revealed that MSK1 is necessary for STAT3 serine phosphorylation. Furthermore, the STAT3-
mediated transactivation was reduced by blocking the STAT3 serine phosphorylation with
the MEK inhibitor U0126 or by expression of kinase-inactive MSK1.
Conclusions. The EPO-induced STAT3 serine 727 phosphorylation is mediated by a pathway
involving MEK, ERK, and MSK1. Furthermore, serine phosphorylation of STAT3 augments
the transactivational potential of STAT3.  2003 International Society for Experimental
Hematology. Published by Elsevier Science Inc.
Hematopoiesis is regulated by a number of cytokines and
growth factors, to accomplish a balanced production of
mature blood cells. A number of lineage-restricted growth
factors has been described, each of them playing a distinct
role in the proliferation and differentiation of speciﬁc cell
lineages. The most important growth factor for the erythroid
lineage is erythropoietin (EPO) [1,2]. EPO is necessary to
stimulate proliferation of erythroid precursor cells, as well
as to induce differentiation of these cells to mature erythro-
cytes[3].EPOexertsitseffectbybindingtotheEPOreceptor
(EPOR) [4], which is composed of two identical subunits.
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Uponligandbinding,thetwosubunitsdimerizeandJanuski-
nases (JAK’s) are recruited to the receptor complex resulting
in the phosphorylation of several tyrosine residues on the
receptor. These phosphorylated tyrosine residues form dock-
ing sites for several molecules, including the signal trans-
ducer and activator of transcription (STAT) transcription
factors. The STAT molecules are phosphorylated on a single
tyrosine residue by JAK kinases, leading to dimerization
and subsequent translocation to the nucleus where they act
as transcription factors [5,6]. Although STAT5 is the most
prominent STAT molecule activated by EPO [7], STAT3
(and STAT1) is also, albeit to a lesser extent, activated by
EPO stimulation [8–10]. The role of STAT3 activation in
the biological function of EPO is not clear. Recent studies
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circumstances, implicating that the two STAT molecules
might be functionally redundant [11,12]. Indeed, although
STAT5A and STAT5B double-knockout mice show ineffec-
tive erythropoiesis, especially under stress conditions [13],
only a modest reduction of the number of circulating eryth-
rocytes is observed in these mice, suggesting that STAT5
is not totally indispensable for correct erythropoiesis [14].
This is in contrast to EPO receptor (EPOR) knockout mice,
which die before birth from defective erythropoiesis in
the fetal liver [15].
Besides tyrosine phosphorylation of STAT3, leading
to nuclear translocation, STAT3 molecules can also be
phosphorylatedonasingleserineresidue,serine727[16,17].
There are conﬂicting data regarding the signiﬁcance of
this serine phosphorylation. It has been shown that serine
727phosphorylationcanreducethetransctivationalpotential
of STAT3, by diminishing the tyrosine phosphorylation and
subsequent binding to its target sequence in promoters [18–
21]. On the other hand, phosphorylation of serine 727 of
STAT3 has also been shown to enhance activation of tran-
scription by STAT3 [16,22–24].
Much effort has been made to identify the kinase(s) re-
sponsible for the serine 727 phosphorylation of STAT3.
Serine 727 in STAT3 (and STAT1 and 4) is situated in a
conserved PMSP motive which resembles the consensus
PxS/TPmotiveformitogen-activatedproteinkinase(MAPK)
targets [25]. Several MAPK family members have been
identiﬁed as kinases capable of phosphorylating serine 727
of STAT3, including extracellular regulated kinase (ERK),
p38 MAPK, and Jun N-terminal kinase (JNK) [20,21,26–
29]. Unrelated kinases such as protein kinase C (PKC) δ
have also been described to be able to phosphorylate STAT3
serine 727 [24,30]. In addition, mitogen and stress-activated
protein kinase 1 (MSK1) was recently described to phospho-
rylate serine 727 of STAT3 in response to ultraviolet irradia-
tion. The activation of MSK1 was found to be mediated by
ERK as well as p38 in this report [31]. The actual kinase
responsible for serine phosphorylation of STAT3 in a given
cell type seems to be dependent on the cellular setting and
the stimulus applied.
In the present study, the pathway leading to serine phos-
phorylationofSTAT3inerythroidcellsisstudied.Itisshown
that serine 727 of STAT3 is phosphorylated by a signal
transduction cascade including MEK, ERK, and MSK1.
Moreover, it is demonstrated that serine phosphorylation of
STAT3 augments the transactivational potential of STAT3
in erythroid cells.
Materials and methods
Cell culture, reagents, and antibodies
ASE2 cells (kindly provided by Dr. M. Tomonaga, Dept. of Hema-
tology, Nagasaki University School of Medicine, Nagasaki, Japan)
were cultured in IMDM with additives (ICN, Costa Mesa, CA,
USA) supplemented with 20% fetal bovine serum (FBS; Bodinco,
Alkmaar, The Netherlands), 2U/mL rh-EPO (Eprex, Jansen Cilag,
The Netherlands), and penicillin-streptomycin (ICN) [32]. Cell
concentration was kept between 0.2 and 1.0 × 106 cells/mL. Stimu-
lation was performed with 10 U/mL rh-EPO, 25 ng/mL interleukin
(IL)-6 (kind gift from Immunex Corp., Seattle, WA, USA), 100
ng/mL stem cell factor (SCF; gift from Immunex Corp.), or 50 nM
phorbolmyristate acetate(PMA)(Sigma,Zwijndrecht,TheNether-
lands). Phoenix amphotropic packaging cells were a kind gift of
Dr. P. Coffer (Dept. Of Pulmonology, University Medical Center,
Utrecht, The Netherlands), and were maintained in DMEM supple-
mentedwith10%fetalcalfserum(FCS)andantibiotics.Antibodies
against phospho-tyrosine 705 of STAT3, phospho-serine 727 of
STAT3, phospho-serine 376 of MSK1, and phospho-threonine 202/
tyrosine 204 ERK were obtained from Cell Signaling (Beverly,
MA, USA). Antibodies against STAT3 (F2) and ERK1 were ob-
tainedfromSantaCruzBiotech(SantaCruz,CA,USA).Antibodies
against MSK1 and phospho-tyrosine 694 STAT5 were obtained
from Upstate Biotechnology (Lake Placid, NY, USA). An antibody
against the FLAG-tag (M2) was obtained from Sigma. HRP-conju-
gated secondary antibodies were obtained from DAKO (Glostrup,
Denmark). PD98059, SB203580, AG490, and Rottlerin were ob-
tained from Biomol (Plymouth Meeting, PA, USA) and used at
concentrationsof50µM, 10 µM,100 µM, and20 µM, respectively.
U0126 (10 µM) was obtained from Promega (Leiden, The Nether-
lands). LY284002 (20 µM) was obtained from Alexis (San Diego,
CA, USA). All other reagents and chemicals were obtained from
Sigma.
cDNA constructs
A ﬂag tagged MSK1(D565A) construct cloned in pCMV5 were
obtained from D. Alessi (MRCP, University of Dundee, Scotland,
UK).A STAT3 luciferase reporter was constructed by ligating three
copiesof theICAM-1 STAT3response element(5′-AGCTTAGGT-
TTCCGGGAAAGCAC-3′) into the pGL3ti vector, which was a
kind gift from Dr. L. Jonk [33]. Exression vectors for STAT3 wild-
type and STAT3 (Ser727 to ala) were gifts from Dr. J.J. Schuringa
(Sloan-Kettering Memorial Institute, New York, NY, USA). An
expression vector for STAT3 with tyrosine 705 mutated to alanine
was a kind gift of Dr. M. Saunders (Devgen NV, Ghent-Zwijn-
gaarde, Belgium) [34]. pDM2lacZ, constitutively expressing β-
galactosidase, is described elsewhere [35]. A retroviral vector
namedpBabe-IRES-EGFP-purowasconstructedbyinsertionofthe
IRES-EGFP cassette from pLZRS into pBabe-puro (both vectors
kindlyprovided by Dr. P. Coffer, Dept. Of Pulmonology, University
Medical Center, Utrecht, The Netherlands). To obtain pBabe-
MSK1(D565A)-IRES-EGFP-puro, the ﬂag-tagged MSK1(D565A)
cDNA was cloned into pBabe-IRES-EGFP-puro. This vector ex-
presses the MSK1 protein and EGFP from the same mRNA
molecule.
Preparation of protein extracts and Western blotting
Before stimulation, ASE2 cells were washed three times with
IMDM and incubated for 16 hours in the presence of 10% FBS
without EPO. To prepare protein extracts, 3 × 106 EPO-deprived
cells per well were plated in 12-well cell culture plates, stimu-
lated, washed, and collected in phosphate-buffered saline (PBS).
Whole-cell lysates were prepared by lysing the cells directly in
Laemmli sample buffer. After SDS-PAGE, proteins were trans-
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blocked with Tris-buffered saline (TBS) buffer containing 0.1%
Tween-20 and 5% nonfat milk prior to incubation with antibodies,
and diluted in TBS containing 5% bovine serum albumin. Binding
of each antibody was detected by the appropriate HRP-conjugated
secondary antibodies using Super Signal (Pierce, Perbio Science,
Etten-Leur, The Netherlands) according to the manufacturer’s
recommendations.
Transient transfections
ASE2 cells were transfected by electroporation. After three washes
with IMDM medium without FBS, 2 × 107 cells were resuspended
in 175 µL IMDM, 25 µg DNA was added, and the mixture was
transferred to a 0.4-cm-gap-width electroporation cuvette. The
cells were pulsed using a Bio-Rad gene pulser electroporation
device (Bio-Rad, Sunnyvale, CA, USA) with 240 V and a capacity
setting of 960 µF. Immediately after pulsing, the cells were trans-
ferred to fresh IMDM media containing 10% FBS and incubated
overnight. For reporter studies, the cells were stimulated for 8
hours andharvested.Cell extractswere madeandluciferase expres-
sion was measured according to the manufacturer’s protocol (Pro-
mega, Leiden, The Netherlands). β-galactosidase expression was
measured to correct for differences in transfection efﬁciency.
Retroviral transductions
MSK1(D565) retroviral particles were produced by transient trans-
fection of pBabe-MSK1(D565A)-IRES-EGFP-puro into Phoenix
amphotropic packaging cells using Fugene6 (Roche, Almere, The
Netherlands) according to the manufacturer’s instructions. After
one day, medium was replaced with IMDM containing 20% FCS.
Two days later, supernatant containing retroviral particles was col-
lected, ﬁltered through a 0.45-µm ﬁlter, and added to ASE2 cells
in the presence of 8 µg/mL polybrene. After one week, GFP+
cells were sorted using MoFlo equipment. GFP+ cells were further
expanded in growth medium and used for Western blotting and
reverse transcriptase polymerase chain reaction (RT-PCR) exper-
iments.
Quantitative RT-PCR
For RT-PCR, total RNA was extracted from 3 × 106 cells, with
TriZol Reagent (Invitrogen, Breda, The Netherlands) according to
the manufacturer’s instructions. Two µg of total RNA was reverse
transcribed using random hexamer priming in a total volume of
20 µL with 200 U MMLv reverse transcriptase (Invitrogen). The
obtained cDNA was diluted to 100 µL, and 2 µL of this solution
was used in a 20-µL PCR reaction with the DNA Master SYBR
Green1 kit (Roche, Almere, The Netherlands) and the indicated
primers using the LightCycler equipment (Roche), according to
the manufacturer’s recommendations. Serially diluted cDNA was
ampliﬁed in parallel with the samples to facilitate quantiﬁcation
oftheamountofspeciﬁccDNApresentineachsample.Therelative
amount of cDNA was calculated using LightCycler software pro-
vided by Roche. All PCR reactions were performed in triplicate.
The sequence of the primers used were (5′→3′): HPRT, forward:
TGGCGTCGTGATTAGTGATG, reverse: GATGTAATCCAG-
CAGGTCAG, c-fos forward: AGCGCAGAGCATTGGCAGGA,
reverse: TCGGTGAGCTGCCAGGATGA, c-myc forward: AC-
CAGCAGCGACTCTGAGGA, reverse: GACGTGGCACCTCT-
TGAGGA.
Results
EPO induces phosphorylation
of STAT3 and STAT5 in erythroid cells
Toinvestigate whichSTATsare activateduponEPOstimula-
tion in erythroid cells, Western blotting using different phos-
pho-speciﬁc anti-STAT3 antibodies was performed. After
deprivationof EPOfor 16hours, ASE2cellswere stimulated
with EPO for different time points. Figure 1A demonstrates
atime-dependentphosphorylationontyrosine705ofSTAT3.
A similar time course was shown for tyrosine phosphoryla-
tion of STAT5. The amount of tyrosine phosphorylation of
STAT3andSTAT5wasmaximalat15minutesofstimulation
and decreased thereafter. Serine phosphorylation of STAT3
was also induced by EPO stimulation and peaked at about
15 to 30 minutes. The serine phosphorylation was not spe-
ciﬁc for ASE2 cells, as similar results were obtained with
the EPO-dependent UT7-EPO cell line (data not shown).
Serine phosphorylation of STAT3
is mediated by an ERK-dependent pathway
Since different signal transduction pathways are described
to be involved in the serine 727 phosphorylation of STAT3,
inhibitor studies were performed to discriminate between
some major pathways. Inhibitors were used to block the
MEK (PD98059 and U0126), p38 (SB203580), PI3K
(LY294002), JAK2 (AG490), and PKCδ (Rottlerin) path-
ways, respectively. ASE2 cells were incubated for 1 hour
with the inhibitors at concentrations known to inhibit their
respective kinases and subsequently stimulated with EPO
for 15 minutes. As shown in Figure 2A, blocking the JAK2
activation by AG490 resulted in a general suppression of
EPO-inducedsignalinginASE2cells,judgedbythestrongly
reduced phosphorylation of STAT3 and 5, as well as the
absence of phosphorylated ERK. The EPO-induced serine
phosphorylation of STAT3 was speciﬁcally blocked by the
MEK inhibitors U0126 and, to a lesser extent, PD98059,
whereas the inhibitors for p38, PI3K, and PKCδ had no
Figure 1. Phosphorylation of STAT molecules by EPO. ASE2 cells were
deprived of EPO overnight, stimulated with EPO (10 U/mL) for different
time points, and whole-cell extracts were blotted against phospho-tyrosine
STAT5, phospho-tyrosine STAT3, and phospho-serine STAT3. The lower
panel shows equal amounts of STAT3 in each sample. Experiments were
performed at least three times; one representative experiment is shown.A.T.J. Wierenga et al./Experimental Hematology 31 (2003) 398–405 401
Figure 2. Serine phosphorylation of STAT3 ismediated by an ERK-depen-
dent pathway. (A) ASE2 cells were stimulated with 10 U/mL EPO for 15
minutes in the absence or presence of the indicated inhibitors. Whole-
cell extracts were prepared and blotted against phospho-tyrosine STAT5,
phospho-tyrosine STAT3, phospho-serine STAT3, and phospho-ERK. The
blots against STAT3 and ERK show equal amounts of protein in each
sample. (B) ASE2 cells were stimulated with IL-6 (20 ng/mL), SCF (100
ng/mL), and PMA (50 ng/mL) for 15 minutes and whole-cell extracts were
blotted against phospho-tyrosine STAT3, phospho-serine STAT3, and phos-
pho-ERK. The lower panel, blotted against STAT3, shows equal amounts
ofproteinineachsample.Offourexperimentsperformed,onerepresentative
experiment is shown.
effect. Tyrosine phosphorylation of STAT3 and STAT5 was
not affected by these inhibitors, excluding possible toxic ef-
fects of these compounds. As expected, the phosphorylation
of ERK was also totally blocked by PD98059 and U0126.
To strengthen the ﬁnding that the serine phosphorylation
of STAT3 was mediated by an ERK-dependent pathway,
two unrelated ERK inducing agents were tested for their
ability to induce serine phosphorylation of STAT3. In Figure
2B, it is shown that both SCF and PMA induce serine
phosphorylation of STAT3 in addition to phosphorylation of
ERK. In contrast, although stimulation with IL-6 resulted
in a clear induction of tyrosine phosphorylation of STAT3,
no induction of ERK or STAT3 serine phosphorylation
was observed.
MSK1 is activated downstream of ERK
Because STAT3 serine 727 phosphorylation has been de-
scribedtobemediatedbyMSK1inﬁbroblasts,theactivation
of MSK1 upon EPO stimulation was investigated. ASE2
cells were stimulated for different time points with EPO and
the lysateswere subsequentlyblotted with antibodiesagainst
phospho-MSK1. Figure 3A shows that MSK1 is activated
after 5 minutes of stimulation and peaked at 15 minutes. To
conﬁrm that MSK1 is activated downstream of ERK, the
MEK inhibitors U0126 and PD98059 were used to block
the MEK-ERK pathway. As demonstrated in Figure 3B,
EPO-induced MSK1 phosphorylation was clearly blocked
by these inhibitors. In contrast, the inhibitors for p38, PI3K,
and PKCδ (SB203580, LY294002, and Rottlerin, respec-
tively) did not inﬂuence the phosphorylation of MSK1 (data
not shown). Furthermore, stimulation with SCF and PMA,
previously shown to induce phosphorylation of ERK and
subsequentserinephosphorylationofSTAT3,alsoresultedin
the activation of MSK1 (data not shown).
MSK1 activation is necessary
for STAT3 serine phosphorylation
To study whether MSK1 activation plays a role in the
phosphorylation of STAT3 on serine 727, retroviral trans-
ductions with kinase-inactive MSK1 (MSK1-D565A) were
performed. ASE2 cells were retrovirally transduced with
empty vector (mock transduced) or with a vector expressing
kinase-inactive MSK1 (D565A). As depicted in Figure 4,
stimulation of mock-transduced cells with EPO resulted
in serine phosphorylation of STAT3. Expression of kinase-
inactive (D565A) MSK1, however, severely reduced the
Figure 3. MSK1 is activated by EPO in an ERK-dependent manner. (A)
ASE2 cells were stimulated with EPO (10 U/mL) for different time points
and whole-cell extracts were blotted against phospho-MSK1. The lower
panel shows equal amounts of MSK1 in each sample. (B) ASE2 cells were
stimulated with 10 U/mL EPO for 15 minutes in the absence or presence of
the indicated inhibitors. The lower panel shows equal amounts of MSK1 in
each sample. Experiments were repeated three times and one representative
experiment is shown.A.T.J. Wierenga et al./Experimental Hematology 31 (2003) 398–405 402
Figure4. MSK1activityisnecessaryforEPO-inducedserinephosphoryla-
tion of STAT3. ASE2 cells were retrovirally transduced with empty vector
(mock) and kinase-inactive MSK1 (D565A), sorted by FACS sorting on
the basis of GFP expression to 99% purity, and used for Western blotting.
Whole-cell lysates were blotted against phospho-serine STAT3, phospho-
tyrosine STAT3,andtotalSTAT3.Expression oftheFLAG-MSK1construct
was conﬁrmedby blottingagainst theFLAG tag. Onerepresentative experi-
ment out of three experiments performed is shown here.
serine phosphorylationof STAT3,showing that MSK1 activ-
ity is necessary for serine phosphorylation of STAT3.
Serine phosphorylation potentiates
the transcriptional activity of STAT3
To address the question of whether serine phosphorylation
inﬂuences the transcriptional activity of STAT3, transactiva-
tion studies were performed. ASE2 cells were transiently
transfected with a luciferase reporter construct containing
three multimerized STAT3 binding sites from the ICAM
promoter. Preliminary experiments revealed that the STAT3
reporter used in these experiments was not sensitive enough
to accurately measure the endogenous STAT3 activation.
Therefore, wild-type STAT3 was cotransfected with the re-
porter in order to be able to quantify the transcriptional
activity of STAT3 in this system. As shown in Figure 5A,
stimulation with EPO resulted in an approximately twofold
increase in luciferase activity. Blocking the ERK-induced
serine phosphorylation of STAT3 with U0126, however,
resulted in 50% reduction of transcriptional activity (1.9-
fold induction vs 1.5-fold induction, respectively, p  0.05).
The EPO-induced STAT5 transactivation, measured with a
STAT5-speciﬁcreporter,wasnotaffectedbyU0126(datanot
shown). Furthermore, as shown in Figure 5B, transfection
of serine 727 to alanine-mutated STAT3 resulted in a similar
reduction of STAT3-mediated transactivation (2.1-fold in-
duction vs 1.6-fold, p  0.05). Transfection of tyrosine 705
to phenylalanine-mutated STAT3 resulted in a lack of re-
sponsetoEPO,asexpected.ThesedataindicatethattheEPO-
induced STAT3 ser 727 phosphorylation by a signaling path-
way involving ERK, is required for maximal transcriptional
activation by STAT3.
Figure 5. Transactivational potential of STAT3 is reduced by inhibition
of STAT3 serine phosphorylation. (A) ASE2 cells were transiently
transfected with a STAT3 reporter plasmid (pGL3-IRE) in the presence of
wild-type STAT3. Cells were subsequently stimulated with EPO (10 U/
mL) for 8 hours and luciferase expression was determined, corrected for
transfectionefﬁciencywithlacZexpression,andexpressedasfoldinduction
compared to unstimulated samples. (B) ASE2 cells were transiently
transfected with wild-type STAT3, ser 727 to ala–mutated STAT3, and
tyr 705 to phe–mutated STAT3. Means and standard deviation of three
experimentsperformed in duplicate areshown; asterisk indicatessigniﬁcant
reduction (p  0.05).
To validate this ﬁnding, we determined the in vivo role
of serine 727 phosphorylation in the activation of gene tran-
scription. Quantitative RT-PCR analysis of two known tar-
getsofSTAT3wasperformedtodeterminetheroleofSTAT3
serine phosphorylation in transcriptional activation of these
endogenous target genes. ASE2 cells were stimulated for 1
hour (in the case of c-fos) or 2 hours (for c-myc) with EPO,
either in the absence or presence of U0126, to inhibit serine
727phosphorylationandthelevelofc-fosand c-mycmRNA
was measured using quantitative RT-PCR analysis. Figure
6A demonstrates that stimulation with EPO resulted in a 26-
fold induction of c-fos mRNA level, which was reduced to
15-fold in the presence of U0126 (p  0.05). EPO-induced
c-myc expression was approximately twofold, and was re-
duced to 1.2-fold by U0126 (p  0.05). RT-PCR analysis
of retrovirally transduced cells, as shown in Figure 6B,A.T.J. Wierenga et al./Experimental Hematology 31 (2003) 398–405 403
Figure 6. EPO-induced c-fos and c-myc mRNA expression is reduced by
inhibitionofSTAT3serinephosphorylation. (A)ASE2cellswerestimulated
with EPO (10 U/mL) for 1 hour (c-fos) or 2 hours (c-myc) in the absence
or presence of U0126. mRNA levels were measured by quantitative RT-
PCR and corrected for amounts of cDNA by RT-PCR of HPRT mRNA
levels. Results are expressed as fold induction compared to unstimulated
samples. (B) ASE2 cells were retrovirally transduced with empty vector
(mock) or kinase-inactive (D565A) MSK1. Cells were stimulated and
mRNA expression was determined as in (A). Means and standard deviation
of a representative experiment performed in triplicate is shown; asterisk
indicates signiﬁcant reduction (p  0.05).
revealed that EPO-induced c-fos mRNA was similarly re-
duced in the presence of a kinase-inactive MSK1 (D565A),
as expected. In the case of c-myc, however, no reduction of
EPO-induced expression could be observed, suggesting that
c-mycexpressionisnottotally dependentuponSTAT3activ-
ity.Insummary,thesedataunderscoretheobservationsusing
reporter genes, that serine 727 phosphorylation is required
for a maximal EPO-induced transcriptional response of
STAT3 target genes like c-fos and, to a lesser extent, c-myc.
Discussion
In this study, the molecular pathway leading to serine 727
phosphorylation of STAT3 in erythroid cells was explored.
It was shown that EPO stimulation of ASE2 cells results in
the rapid phosphorylation of STAT3 on both tyrosine 705
andserine727.TheEPO-inducedphosphorylationofSTAT3
on tyrosine 705 has been described before in other erythroid
cells, such as UT-7/EPO [9]. In these cells, it was found that
tyrosine residue 432 of the EPOR mediates the activation
of STAT3 upon EPO stimulation, whereas STAT5 tyrosine
phosphorylation was mediated by the three most proximal
tyrosine residues. Apart from tyrosine phosphorylation,
STAT3 was also phosphorylated on serine 727 by EPO stim-
ulation. A number of different pathways have been impli-
cated in serine 727 phosphorylation of STAT3. In this study,
the MEK-ERK-MSK1 pathway was identiﬁed as the pri-
mary route leading to STAT3 serine 727 phosphorylation.
Severallinesofevidencepointtowardthisconclusion.Using
inhibitors for several pathways, only the MEK inhibitors
PD98059 and U0126 speciﬁcally inhibited the serine 727
phosphorylation.Furthermore,SCFandPMA,twounrelated
ERK-inducingagents,werealsoeffectiveinmediatingserine
727 phosphorylation of STAT3. During the preparation of
this manuscript, Haq et al. described a similar induction of
STAT3 serine 727 phosphorylation by EPO in BaF3 cells
expressing the EPO receptor [36]. In these cells, the MEK
pathway was also identiﬁed to be responsible for the serine
727 phosphorylation. Our study extends this ﬁnding further
by identifying the downstream kinase responsible for the
serine 727 phosphorylation. MSK1 is a nuclear kinase, iden-
tiﬁed as a target of ERK, JNK, and p38, and implicated
in phosphorylation of CREB and ATF1. MSK1 is activated
in an ERK-dependent manner in ASE2 cells upon EPO
stimulation, as the inhibitors PD98059 and U0126 could
block the MSK1 phosphorylation. In mouse JB6 Cl 41 cells,
ultraviolet A irradiation resulted in activation of MSK1 and
the subsequent serine 727 phosphorylation of STAT3 [31].
In this cell system, both the MEK inhibitor PD98059 and
thep38inhibitorSB202190blockedtheactivationofMSK1.
In contrast to the latter ﬁnding, in ASE2 cells the p38 inhibi-
torSB203580didnotshowanyeffectonthephosphorylation
of MSK1 (data not shown), so whether p38 is not activated
by EPO in ASE2 cells, or p38 does not play a role in the
activation of MSK1 in ASE2 cells, is at present unknown.
We show in the present study that MSK1 is necessary for
theserine727phosphorylationofSTAT3,sinceexpressionof
amutantproteinwithaninactivatedkinasedomainabrogated
the serine 727 phosphorylation. Zhang et al. [31] already
identiﬁed MSK1 as a kinase capable of phosphorylating
serine 727 in STAT3 by using an in vitro kinase assay.
Therefore it is conceivable that in our cell system, MSK1
is responsible for the phosphorylation of STAT3 serine 727.
However, we cannot rule out the possibility that another
intermediate kinase is located between MSK1 and STAT3
and is actually the direct kinase for STAT3.
Theroleofserine727phosphorylationintheregulationof
thetranscriptionalpotentialofSTAT3isnotwellunderstood.
Some studies report a reduced tyrosine phosphorylation
and binding of STAT3 to its target sequence upon serine
phosphorylation. Additional studies describe an enhancing
effect of STAT3 serine 727 phosphorylation on the transcrip-
tional potential of STAT3. STAT3β, an alternatively spliced
variant of STAT3 lacking serine 727, has been described
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STAT3 molecules with serine 727 to alanine mutations have
been described to have decreased transactivational potential
[23]. In our study, serine 727 phosphorylation was shown
toincreasethe transactivationalpotentialofSTAT3. Withthe
use of a STAT3 reporter, we were able to show that blocking
serine 727 phosphorylation by U0126 resulted in a dimin-
ished transactivation. In accordance with this, expression of
a serine 727 to alanine-mutated STAT3 resulted in a dimin-
ished STAT3-mediated transactivation. By analyzing the
EPO-induced expression of STAT3 target genes, we showed
that expression of c-fos and c-myc were inhibited by U0126,
underscoring the results with the reporter construct. Expres-
sion of c-fos mRNA was also reduced in the presence of a
kinase-inactiveMSK1construct,asexpectedfromtheresults
with the MEK inhibitor U0126. EPO-induced expression
of c-myc, however, was not affected by the expression of
kinase-inactive MSK1. The cause of this discrepancy be-
tweentheresultswiththekinase-inactiveMSK1andtheMEK
inhibitor U0126 is not clear. Probably other signal trans-
duction pathways play a role in the regulation of c-myc ex-
pression. Interactions between AP-1 and STAT3 have been
described, leadingtoenhancedSTAT3-mediatedtransactiva-
tion [37]. This enhancement of STAT3 transactivation has
been shown to be sensitive to the MEK inhibitor PD98059,
possiblyexplainingthereducedc-mycexpressionuponincu-
bation with U0126. This would suggest that the expression
of c-myc is regulated by multiple factors, including STAT3,
instead of STAT3 binding alone.
In conclusion, the present study describes the identiﬁca-
tion of the MEK-ERK-MSK1 pathway as the route responsi-
ble for the EPO-induced STAT3 serine 727 phosphorylation,
andthatthisphosphorylationleadstoanincreaseintransacti-
vational potential of STAT3 in erythroid cells.
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